Ishita Drugs & Industries Ltd (ISHITADR) is currently trading at 72.72 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ishita Drugs & Industries Limited specializes in manufacturing Active Pharma Ingredients, drug intermediates, fine chemicals, and excipients, with state-of-the-art production facilities. The company boasts three key manufacturing facilities in Gujarat, dedicated to APIs, drug intermediates, and pharmaceutical formulations. With origins tracing back to 1981, Ishita Drugs has evolved into a vertically integrated chain covering various pharmaceutical production segments. The company initiated a bulk drugs manufacturing project at Sanand, Gujarat in 1995, marking a significant capacity expansion in the industry. Ishita Drugs has demonstrated technological advancement, with improved process technologies implemented, particularly for norfloxacin in its manufacturing.

Over the past 52 weeks, Ishita Drugs & Industries Ltd has traded between a low of ₹66.00 and a high of ₹90.85. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ishita Drugs & Industries Ltd has a market capitalization of approximately 21.71. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ishita Drugs & Industries Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.74 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 21.71 Cr, Ishita Drugs & Industries Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ishita Drugs & Industries Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ishita Drugs & Industries Ltd is 29.74. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Ishita Drugs said on 3 November 2026 that civil work in the current project phase was nearing completion. Renovation of existing buildings, construction of new blocks, equipment deliveries and utility work were part of the disclosed activity.

Ishita Drugs is scheduled to hold its board meeting on November 3, 2026, to consider and approve unaudited Q2 FY27 results. The results relate to the quarter ended September 30, 2026.

The board meeting is scheduled for Saturday, May 30, 2026.